Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.

ABSTRACT:

Unlabelled

There is currently no licensed vaccine for noroviruses, and development is hindered, in part, by an incomplete understanding of the host adaptive immune response to these highly heterogeneous viruses and rapid GII.4 norovirus molecular evolution. Emergence of a new predominant GII.4 norovirus strain occurs every 2 to 4 years. To address the problem of GII.4 antigenic variation, we tested the hypothesis that chimeric virus-like particle (VLP)-based vaccine platforms, which incorporate antigenic determinants from multiple strains into a single genetic background, will elicit a broader immune response against contemporary and emergent strains. Here, we compare the immune response generated by chimeric VLPs to that of parental strains and a multivalent VLP cocktail. Results

SUBMITTER: Debbink K 

PROVIDER: S-EPMC4054422 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature